EMERYVILLE, Calif., Feb 10, 2010 /PRNewswire via COMTEX/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today the appointment of quality control and botanical authentication expert, Paul Pui-Hay But, Ph.D., to the company's Scientific Advisory Board. Dr. But is the Chief Scientist for the Food and Drug Authentication Laboratory Ltd., Hong Kong, China, and a leading investigator and consultant on botanical authentication and Chinese medicine quality control.
"We are honored to have Dr. Paul But join our Scientific Advisory Board, given his well established expertise in the field of botanical authentication and Chinese medicine quality control. Dr. But has over thirty years of experience in these areas, and has particular expertise in an area that can be of great benefit to Bionovo, the DNA-based authentication and quality assessment of Chinese medicinal materials," said Isaac Cohen, OMD, Bionovo's Chairman and Chief Executive Officer.
Dr. But states, "I have been observing with interest Bionovo's growth and progress in recent years and especially appreciate the direction and focus Bionovo has chosen. It will be gratifying to work with Bionovo, and to be given a chance to participate in the development of such important drug therapies. I am happy to contribute to Bionovo's efforts regarding the sourcing and authentication of quality medicinal material."
Dr. But holds bachelor's and master's degrees from The Chinese University of Hong Kong (CUHK), and holds master's and doctoral degrees from the University of California, Berkeley. He has held positions of distinction at CUHK as well as with Hong Kong government committees focused on Chinese medicine, medicinal material research, and quality control. Dr. But has eleven issued patents, including patents of DNA sequences and polymerase chain reaction (PCR) restriction fragment length polymorphism testing for the authentication of traditional Chinese medicines. Dr. But has over 230 publications spanning thirty years.
Bionovo is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit http://www.bionovo.com/.
Forward Looking Statements
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov/. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
SOURCE Bionovo, Inc.